Never change a winning team
Parma/Baranzate – Chiesi Farmaceutici Spa has said it will lengthen its long-term collaboration with NiKem Research, which is focused on developing treatments within the respiratory therapeutic area.
The two drug developers have been cooperating since 2001, and the new deal will extend their efforts until 2014.
Chiesi specialises in products for respiratory pathologies, special care medicine and cardiovascular diseases. Its revenues exceeded a1bn in 2010. Chiesi is working together with NiKem on the development of preclinical candidates. NiKem Research was founded in 2001 as a spin-off from the GSK Research Centre in Baranzate near Milan, and has a staff of about 60.
NiKem is providing the collaboration’s design, synthesis, hit validation, and lead optimisation. The firm’s CEO Giuseppe Giardina described the partnership as “rock solid”, and said that the “current extension follows 10 years of continuous success.”